Pages that link to "Q38798543"
Jump to navigation
Jump to search
The following pages link to Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. (Q38798543):
Displaying 50 items.
- Genomic Evolution of Breast Cancer Metastasis and Relapse (Q38623761) (← links)
- Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes (Q38627087) (← links)
- Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations (Q38628202) (← links)
- Managing the genomic revolution in cancer diagnostics (Q38714606) (← links)
- The Evolving Genomic Landscape of Barrett's Esophagus and Esophageal Adenocarcinoma (Q39440077) (← links)
- Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β. (Q41348786) (← links)
- Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. (Q41571663) (← links)
- Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. (Q42261796) (← links)
- Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma (Q42698863) (← links)
- PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients (Q45069110) (← links)
- Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy. (Q46574283) (← links)
- Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients (Q46754264) (← links)
- The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2). (Q46861636) (← links)
- Molecular determinants of prostate cancer metastasis (Q47103669) (← links)
- TissGDB: tissue-specific gene database in cancer. (Q47105299) (← links)
- Somatic mutations in CDH1 and CTNNB1 in primary carcinomas at 13 anatomic sites. (Q47107732) (← links)
- Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. (Q47108754) (← links)
- Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. (Q47141518) (← links)
- Interactive or static reports to guide clinical interpretation of cancer genomics (Q47190133) (← links)
- Personalized cancer therapy: leveraging a knowledge base for clinical decision-making (Q47199187) (← links)
- Implementation of "Clinical Sequencing" in Cancer Genome Medicine in Japan (Q47235804) (← links)
- Targeting mutant p53 for efficient cancer therapy. (Q47291772) (← links)
- Tumor Origin Detection with Tissue-Specific miRNA and DNA methylation Markers (Q47314355) (← links)
- DNAJB1-PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. (Q47377422) (← links)
- RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition (Q47415053) (← links)
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. (Q47584566) (← links)
- PD-1/PD-L1 Axis in Lung Cancer (Q47717168) (← links)
- Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. (Q47768051) (← links)
- New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. (Q47979409) (← links)
- The Value of Cell-free DNA for Molecular Pathology (Q48143437) (← links)
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (Q48156858) (← links)
- Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study. (Q48218531) (← links)
- Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers. (Q48262529) (← links)
- KRAS Alleles: The Devil Is in the Detail (Q49668169) (← links)
- Preclinical and clinical development of neoantigen vaccines (Q49668436) (← links)
- Genomic alterations of ERBB receptors in cancer: clinical implications (Q49678076) (← links)
- Development of new preclinical models to advance adrenocortical carcinoma research (Q49681867) (← links)
- Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. (Q49710712) (← links)
- Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer (Q49734875) (← links)
- Accelerating Discovery of Functional Mutant Alleles in Cancer (Q49790712) (← links)
- Functional Analysis of Cancer-Associated DNA Polymerase ε Variants in Saccharomyces cerevisiae (Q49911660) (← links)
- Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing (Q50027697) (← links)
- Making Use of Cancer Genomic Databases (Q50030738) (← links)
- Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. (Q50049563) (← links)
- BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi (Q50053521) (← links)
- Fishing for answers in precision cancer medicine (Q50061359) (← links)
- Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway (Q50067502) (← links)
- Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology (Q50095063) (← links)
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers (Q50115014) (← links)
- PRECISION ONCOLOGY DECISION SUPPORT: CURRENT APPROACHES AND STRATEGIES FOR THE FUTURE. (Q50115884) (← links)